Männedorf, Switzerland 7/15/10; Poway, CA 7/15/10—Tecan has announced an agreement to sell its REMP AG subsidiary and related assets to NEXUS Biosystems, a supplier of sample management systems, for CHF 12 million ($11 million = CHF 1.06 = $1) and additional deferred payments of $4.4–$7.7 million. Based in Oberdiessbach, Switzerland, with 120 employees, REMP provides […]
Santa Clara, CA 7/7/10—Affymetrix has announced that it expects second-quarter revenues to be $71–$72 million, compared to its earlier guidance of $80–$82 million (see IBO 5/15/10). Product revenue is forecast to be approximately $65–$66 million, including $4–$5 million in instrument sales and consumables sales of $60–$61 million. The company stated three primary reasons for the […]
Breeding crops has always been an art and a science. With genetic markers now playing a larger role in breeding, the science is beginning to outweigh the art. According to the US Department of Agriculture, in the US alone, public spending for agricultural research in 2008 reached $4.0 billion. Genomic analysis tools have changed crop […]
In calendar-year (CY) 2009, total R&D spending in US dollars for 18 major publicly held analytical and life science instrument and laboratory product companies (see table, page 6) grew 0.7% to $1.52 billion, compared to 9.2% in CY08. R&D spending outperformed revenue growth, which declined 2.8% for the 18 companies in CY09. As a result, […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
